Volume 80, Issue 6 (September 2022)
Tehran Univ Med J 2022, 80(6): 462-469 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Razazian N, Sahraian M, Eskandarieh S, Jafari N, Rezaei M, Fakhri N. Outcomes of AstraZeneca vaccine for relapse and Covid-19 infection in people with multiple sclerosis. Tehran Univ Med J 2022; 80 (6) :462-469
URL: http://tumj.tums.ac.ir/article-1-11869-en.html
URL: http://tumj.tums.ac.ir/article-1-11869-en.html
Outcomes of AstraZeneca vaccine for relapse and Covid-19 infection in people with multiple sclerosis
Nazanin Razazian1 
, Mohammad-Ali Sahraian2 , Sharareh Eskandarieh2 , Nooshin Jafari1 , Mansour Rezaei3 , Negin Fakhri * 4
, Mohammad-Ali Sahraian2 , Sharareh Eskandarieh2 , Nooshin Jafari1 , Mansour Rezaei3 , Negin Fakhri * 4
1- Department of Neurology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2- Multiple Sclerosis Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Biostatistics, Social Development and Health Promotion Research Center, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
4- Department of Biostatistics, Student’s Research Committee, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ,n.fakhri94@yahoo.com
2- Multiple Sclerosis Research Center, Neuroscience Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Biostatistics, Social Development and Health Promotion Research Center, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
4- Department of Biostatistics, Student’s Research Committee, Faculty of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ,
Abstract: (821 Views)
Background: People with chronic diseases of the immune system, such as multiple sclerosis (MS), are at risk for Covid-19 disease. However, more research is needed with long-term follow-up. The aim of the study was to follow up people with MS (PwMS) for up to three months after AstraZeneca vaccination for the recurrence of MS and Covid-19 infection.
Methods: This study was a case study (descriptive-analytical) of follow-up type. The study population was PwMS over 18 years of age in Kermanshah province who received both doses of the AstraZeneca vaccine. This study was conducted from August to November 2021. Sampling was done with existing methods based on the National MS Registry of Iran (NMSRI). Demographic information of patients was extracted from NMSRI. A researcher-made form was used to collect information by telephone three months after vaccination about clinical characteristics, Covid-19 infection, and recurrence of MS. Data were analyzed using SPSS-25 software.
Results: Study participants were 40 MS patients with a mean (SD) age of 39.27 (8.8) years, including 32 (80.0%) women. A mean of 9.39 (4.6) years had passed since The patients were diagnosed with MS, and 29 (76.4%) had RR type MS. Four patients (10%) relapsed between the second dose and three months later, of whom two (50%) had sensory symptoms, one (25%) had optic nerve involvement, and one (25%) had motor symptoms and pyramidal pathway involvement. The symptoms of Covid-19 were mild in three patients (10%), while severe symptoms developed in one patient (10%) who received rituximab. Among the patients, no cases of thrombosis were observed. Infusion therapy, a leg fracture, and kidney stones were the only hospitalized cases.
Methods: This study was a case study (descriptive-analytical) of follow-up type. The study population was PwMS over 18 years of age in Kermanshah province who received both doses of the AstraZeneca vaccine. This study was conducted from August to November 2021. Sampling was done with existing methods based on the National MS Registry of Iran (NMSRI). Demographic information of patients was extracted from NMSRI. A researcher-made form was used to collect information by telephone three months after vaccination about clinical characteristics, Covid-19 infection, and recurrence of MS. Data were analyzed using SPSS-25 software.
Results: Study participants were 40 MS patients with a mean (SD) age of 39.27 (8.8) years, including 32 (80.0%) women. A mean of 9.39 (4.6) years had passed since The patients were diagnosed with MS, and 29 (76.4%) had RR type MS. Four patients (10%) relapsed between the second dose and three months later, of whom two (50%) had sensory symptoms, one (25%) had optic nerve involvement, and one (25%) had motor symptoms and pyramidal pathway involvement. The symptoms of Covid-19 were mild in three patients (10%), while severe symptoms developed in one patient (10%) who received rituximab. Among the patients, no cases of thrombosis were observed. Infusion therapy, a leg fracture, and kidney stones were the only hospitalized cases.
|
Conclusion: Covid-19 and MS relapse prevalence did not differ significantly in the three months before and after vaccination. There is a need for further studies with a longer follow-up period.
|
Type of Study: Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
